Liver Enzymes and Inpatient Deaths in COVID-19 Hospitalized Patients
| Author | Mahmoodreza Khoonsari | en |
| Author | Farhad Zamani | en |
| Author | Mohammad Hadi Karbalaie Niya | en |
| Author | Gholamreza Hemmasi | en |
| Author | Hossein Ajdarkosh | en |
| Author | Amirhossein Faraji | en |
| Author | Mehdi Nikkhah | en |
| Author | Elham Pishgar | en |
| Author | Mahin Jamshidi Makiani | en |
| Author | Mitra Ranjbar | en |
| Author | Fahimeh Safarnezhad Tameshkel | en |
| Author | Mahshid Panahi | en |
| Author | Mitra Ameli | en |
| Author | Mahdi Yadollahzadeh | en |
| Author | Mohsen Farrokhpour | en |
| Author | Mansooreh Maadi | en |
| Author | Abolfazl Ghafari | en |
| Author | Marzieh Valuiyan | en |
| Author | Masoume Pouladi | en |
| Author | Nima Motamed | en |
| Orcid | Farhad Zamani [0000-0001-7409-3412] | en |
| Orcid | Mohammad Hadi Karbalaie Niya [0000-0002-1364-5743] | en |
| Orcid | Fahimeh Safarnezhad Tameshkel [0000-0001-8953-5447] | en |
| Orcid | Mahshid Panahi [0000-0001-8005-3273] | en |
| Issued Date | 2020-11-30 | en |
| Abstract | Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [COVID-19] quickly turned into a pandemic. Gastrointestinal involvement, especially liver diseases, is one of the main complications of COVID-19 patients. Objectives: The current study aimed to evaluate the high incidence of liver involvement in COVID-19 hospitalized patients and its association with mortality. Methods: A total of 560 hospitalized patients with a confirmed diagnosis of COVID-19 were included. Death was considered as the outcome. In addition to liver enzymes, demographic, clinical, and other laboratory data were also collected. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≥ 40 were considered as abnormal. To investigate the association between abnormal levels of liver enzymes and death, multiple regression logistic was used. Results: According to the findings, 29.1% (95% CI = 25.3% - 32.9%) of patients had high levels (≥ 40 IU) of ALT, and 45.1% (95% CI = 40.9% - 49.3%) had high levels of AST (≥ 40 IU). The frequency (based on %) of high levels of AST (≥ 40 U/liter) was significantly higher in patients who died [67.3% (95% CI = 54.5% - 80.1%] of COVID-19 than those who survived [44.9% (95% CI = 39.7% - 50.0%)] (P-value < 0.001). No significant difference was detected in ALT between expired [29.1% (95% CI = 16.7% - 41.5%)] and survived patients [30.7% (95% CI = 25.9% - 35.5%] (P-value = 0.791). AST was found to have an independent association with death in multiple logistic regression (Wald = 4.429, OR (95% CI) = 1.014 (1.008 - 1.020), P-value = 0.035). Conclusions: Liver involvement is a common finding in COVID-19 hospitalized patients. Higher levels of AST were significantly associated with an increased mortality rate in COVID-19 patients. | en |
| DOI | https://doi.org/10.5812/hepatmon.109076 | en |
| Keyword | COVID-19 | en |
| Keyword | Mortality | en |
| Keyword | Liver Disease | en |
| Keyword | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | en |
| Publisher | Brieflands | en |
| Title | Liver Enzymes and Inpatient Deaths in COVID-19 Hospitalized Patients | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- hepatmon-20-11-109076.pdf
- Size:
- 140.58 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF